Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the safety and effectiveness of Concerta in the
treatment of children (ages 5 to 17 years old) and adults (ages 18 to 55 years old) with
Bipolar I, Bipolar II and Bipolar Spectrum Disorder and comorbid ADHD over 8 weeks. This
study seeks to study the short-term effectiveness of a long acting formulation of
methylphenidate (Concerta) in the treatment of children and adults with bipolar disorder and
comorbid ADHD adequately stabilized on an acceptable and stable regimen of anti-mania agents.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.